Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prophylactic effect of bestatin on the onset of invasive mole — clinical and fundamental studies

Abstract

This study was performed to determine whether bestatin (Ubenimex) has clinical prophylactic effects on the onset of invasive mole and a direct inhibitory effect on the growth of hydatidiform molar cells. A total of 49 patients with hydatidiform mole treated at Nagoya University Hospital from 1984 to 1990 were randomly divided into two groups, a bestatin administered-group and a bestatin non-administered group. Patients in the bestatin group were given 30 mg of bestatin orally and daily for three months just after their molar deliveries. There was no significant difference in age, gravidity, parity and gestational weeks between the two groups. There was also no significant difference in the duration of human chorionic gonadotropin (hCG) negative conversion in patients without invasive mole between the two groups. However, the incidence of invasive mole in the bestatin group (2/25, 8%) was significantly lower than that of the non-bestatin group (7/24, 29.2%). Nevertheless, there was no significant difference between the two groups in such immunological parameters as PHA skin test, PPD skin test, PHA stimulation index (PHA-SI), white blood cell (WBC) count lymphocytes % per WBC, OKT 3% per lymphocytes, OKT 4% per lymphocytes, OKT4/OKT8 and Leu 11% per lymphocytes. In vitro studies were performed with primary cultured hydatidiform moles. The result was that bestatin inhibited the secretion of hCG and3H-thymidine uptake of hydatidiform molar cells. Thus, a possibility was suggested that bestatin directly inhibits the growth of hydatidiform molar cells and prevents the onset of invasive mole.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Tomoda Y. Incidence of trophoblastic disease. In: Ishizuka N, Tomoda Y, eds. Gestational trophoblastic disease. Nagoya, Japan: The University of Nagoya Press, 1990: 5.

  2. 2.

    Ayhan A, Ergeneli MH, Yuce K, Yapar EG, Kisnsci AH. Effects of prophylactic chemotherapy for postmolar trophoblastic disease in patients with complete hydatidiform mole. Int J Gynecol Obstet 1990; 32: 39–41.

  3. 3.

    Hirokawa K, Tomoda Y, Kaseki S, Ishizuka T, Nishikawa Y, Goto S. Recurrence of invasive moles and choriocarcinoma. Asia-Oceania J Obstet Gynecol 1986; 12: 11–20.

  4. 4.

    Bagshawe KD, Dent J. Hydatidiform mole in England and Wales 1973–83. Lancet 1986; 2: 673–7.

  5. 5.

    Abe F, Fujii A, Yoshimura K, Yugeta E, Ishizuka M, Takeuchi T. Immunomodulatory and therapeutic characteristics of bestatin (Ubenimex) Int J Immunotherapy 1990; 4: 203–9.

  6. 6.

    Suzuki N, Konishi E, Kondo K, Fujita I, Ishikawa E. A highly sensitive colorimetric sandwich-enzyme immunoassay for human chorionic gonadotropin using specific antibodies against the carboxy-terminal portion of the beta-subunit. Clin Chim Acta 1985; 150: 247–53.

  7. 7.

    Koyama M, Hashimoto M, Asakawa M, Miyazaki H Simultaneous determination of bestatin and p-hydroxy bestatin, a major metabolite, in human serum by gas chromatography mass spectrometry. Biomed Mass Spectom 1980;7: 372–6.

  8. 8.

    Umezawa H, Aoyagi T, Hamada M, et al. Bestatin, an inhibitor of aminopeptidase B, produced by actinomyces. J Antibiot 1976; 29: 97–9.

  9. 9.

    Umezawa H. Low-molecular-weight immunomodifiers produced by micro-organisms. Biotechnology and genetic engineering reviews 1985; 3: 255–73.

  10. 10.

    Ishizuka M. Fundamental study on a low molecular immunomodifier, Ubenimex. Gann Monograph on cancer Research 1989; 36: 147–55.

  11. 11.

    Ikeda S, Ishihara K. Randomized, controlled study of bestatin in the treatment of stage Ib and II malignant melanoma. Int J Immunother 1986; 2: 73–9.

  12. 12.

    Ota K, Ogawa N. Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults. Biomed & Pharmacother 1990; 44: 93–102.

  13. 13.

    Kumano N, Suzuki S, Oizumi K, Konno K, Himori T and Mitachi Y. Imbalance of T cell subsets in cancer patients and its modification with bestatin, a small molecular immunomodifier Tohoku J ex Me 1985; 147: 125–33.

  14. 14.

    Miura K, Sawa T, Takeuchi T, Umezawa H. Effect of enzyme inhibitors in inhibiting the growth and inducing the differentiation of human promyelocytic leukemia cells, HL-60. J Antibiot 1986; 39: 734–5.

  15. 15.

    Ino K, Goto S, Kosaki A, Asada A, Misawa T, Furuhashi Y, Mizutani S, Tomoda Y. Growth inhibitory effect of bestatin on choriocarcinoma cell linesin vitro. Biotherapy 1991; 3: 351–7.

  16. 16.

    Okuyama S, Mishina H, Maki T. Redifferentiation of cancer cells: Bestatin, estradiol, and prostaglandin D2. Annals of the New York Academy of Sciences 1985; 459: 293–307.

  17. 17.

    Kurauchi O, Mizutani S, Okano K, Narita O, Tomoda Y. Purification and characterization of human placental microsomal aminopeptidase: Immunological difference between placental microsomal aminopeptidase and pregnancy serum cystyl-aminopeptidase. Enzyme 1986; 35: 197–205.

  18. 18.

    Look AT, Ashmun RA, Shapiro LH, Peiper SC. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J Clin Invest 1989; 83: 1299–307.

  19. 19.

    Ashmun RA, Look AT. Metalloprotease activity of CD13/Aminopeptidase N on the surface of human myeloid cells. Blood 1990; 75: 462–9.

  20. 20.

    Khokha R, Denhardt DT. Matrix metal loproteinases and tissue inhibitor of metallopeptidases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 1989; 9: 391–405.

  21. 21.

    Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1990; 82: 1890–8.

  22. 22.

    Saiki I, Murata J, Watanabe K, Fujii H, Abe F, Azuma I. Inhibition of tumor cell invasion by Ubenimex (Bestatin)in vitro. Jpn J Cancer Res. 1989; 80: 873–8.

  23. 23.

    Kashimura Y, Kashimura ML Sugimori H, Tsukamoto N, Matsuyama T, Matsuyama K, Kamura T, Saito T, Kawano H, Nose R, Nose Y, Nakano H, Taka I. Prophylactic chemotherapy for hydatidiform mole. Cancer 1986; 58: 624–9.

  24. 24.

    Saito K, Miyazato H, Tazima K, Ikeda, S. Phase I study of bestatin: a clinical study on determination of an optimal dose of bestatin. Jpn J Cancer Chemother 1983 10(2); PART 1 211–7.

Download references

Author information

Correspondence to Dr. Hisao Mano.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Asada, E., Mano, H., Yamada, A. et al. Prophylactic effect of bestatin on the onset of invasive mole — clinical and fundamental studies. Biotherapy 5, 145–152 (1992). https://doi.org/10.1007/BF02171700

Download citation

Key words

  • bestatin
  • BRM
  • hydatidiform mole
  • invasive mole
  • prophylactic effect